Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.75 |
| ▸ | NPC1 | O15118 | 5/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.72 |
| ▸ | RELA | Q04206 | 1/20 | 0.72 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.69 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.69 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.69 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.69 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.69 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471759 | 0.90 | MAPT (0.77) | TRPV1NPC1RAB9AALDH1A1MAPT | |
| SCHEMBL8012743 | 0.89 | TRPV1 (0.81) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7636110 | 0.86 | TRPV1 (0.77) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL19501635 | 0.86 | TRPV1 (0.77) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL8265643 | 0.85 | TRPV1 (0.71) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1996813 | 0.84 | TRPV1 (0.75) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18423189 | 0.84 | TRPV1 (0.75) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7834640 | 0.84 | TRPV1 (0.75) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13389060 | 0.84 | MAPT (0.77) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18422082 | 0.83 | TRPV1 (0.73) | TRPV1NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174947-B2 | c-Met modulators and methods of use | Exelixus, Inc. (US) | 2015-11-03 | — | — | US | disclosed |
| US-8178532-B2 | c-Met modulators and method of use | EXELIXIS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8067436-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | TRPV1 4053/4885NPC1 3618/4885RAB9A 3070/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | TRPV1 4059/4885NPC1 3103/4885RAB9A 3398/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | TRPV1 4401/4885NPC1 3278/4885RAB9A 3215/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | TRPV1 4378/4885NPC1 3357/4885RAB9A 3263/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | TRPV1 4378/4885NPC1 3357/4885RAB9A 3263/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | TRPV1 4401/4885NPC1 3278/4885RAB9A 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.